Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05616468 | BGT007 Cell Treatment of Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 23 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05638256 | 68Ga-labeled NY104 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05003427 | 68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05589961 | Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme | unknown | Early Phase 1 | 10 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT04974281 | PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC | unknown | Early Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05013372 | CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | unknown | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05480501 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05459441 | Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases | unknown | Early Phase 1 | 30 | Shanghai Pudong HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 100 | Zhejiang UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05382377 | NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05364177 | 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05087264 | Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | unknown | Early Phase 1 | 86 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05287165 | Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms | unknown | Early Phase 1 | 19 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05252572 | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05239676 | Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | unknown | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05239689 | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | unknown | Early Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05154812 | Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio | unknown | Early Phase 1 | 108 | Beijing Ditan HospitalOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05152498 | Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC) | unknown | Early Phase 1 | 142 | Beijing Ditan HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05008536 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05088733 | Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA) | unknown | Early Phase 1 | 120 | Beijing Ditan HospitalOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05105815 | Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma | unknown | Early Phase 1 | 23 | Huashan HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04617704 | BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03943472 | BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 10 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT03347097 | Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme | unknown | Early Phase 1 | 40 | Huashan HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT05016063 | Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | unknown | Early Phase 1 | 32 | Xinqiao Hospital of ChongqingOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05009446 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM(SNMM) | unknown | Early Phase 1 | 28 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT05007587 | Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC | unknown | Early Phase 1 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT05001204 | 68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04951141 | Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2021 | clinicaltrials |
| NCT04264078 | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04236011 | BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04919616 | An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 15 | Shanghai OriginCell Therapeutics Co., Ltd.INDUSTRY | 0 | Jun 9, 2021 | clinicaltrials |
| NCT03795779 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04864821 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | unknown | Early Phase 1 | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 0 | May 6, 2021 | clinicaltrials |
| NCT04801264 | Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 | unknown | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | unknown | Early Phase 1 | 18 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04753918 | Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study | unknown | Early Phase 1 | 3 | Taoyuan General HospitalOTHER_GOV | 0 | Feb 15, 2021 | clinicaltrials |
| NCT04439721 | γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse(γδT) | unknown | Early Phase 1 | 5 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04696705 | Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients | unknown | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2022source: clinicaltrials